THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...

EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...

CStone Pharma announces inclusion of Cejemly as a first-line combination therapy for NSCLC in ESMO guideline: Suzhou, China Tuesday, February 11, 2025, 13:00 Hrs [IST] CStone Phar ...

Each year, Phesi releases an analysis of the world’s most studied diseases. The survey includes data from the 67,569 ...

PRR15 作为一种在胎盘发育中起关键作用的核蛋白，此前在肿瘤研究领域关注度较低。虽有研究表明其在胃肠道肿瘤、乳腺癌和结肠腺癌等疾病中存在异常表达，但在 NSCLC 中的具体功能尚未明确。本研究旨在填补这一空白，深入剖析 PRR15 在 NSCLC 中的作用机制，为临床治疗提供新的思路和靶点。

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The American Association for Cancer Research Annual Meeting 2025 will be held from April 25-30 in Chicago, Illinois, providing a ...

Dr Zaheer Mangera discusses the evolution of the neoadjuvant lung cancer pathway and notable changes to the TNM standards.

Jones Trading reiterated a Buy rating on ORIC Pharmaceuticals stock with a price target of $17.00, as shares traded at $11.23. The stock has shown remarkable momentum, gaining over 20% in the past ...

基石药业昨日公布，公司重磅产品舒格利单抗（择捷美®）被纳入《欧洲肿瘤内科学会非驱动基因阳性转移性非小细胞肺癌动态临床指南》 （ESMO NonOncogene-Addicted Metastatic Non-Small-Cell Lung ...